OPKO in the first quarter: a smaller business, a narrower loss, and still no self-funding model

Company Overview

OPKO opened 2026 with a quarter that cuts in two directions. Revenue fell to $124.2 million, down 17% year over year, mainly because BioReference’s oncology business is no longer in the numbers. But the operating loss narrowed to $51.0 million from $67.2 million, and the net loss narrowed to $54.8 million from $67.6 million. The business is smaller, but it is also burning less.

The piece that is working is the pharmaceutical side. Product revenue rose 9%, intellectual property and collaboration revenue rose 14%, and NGENLA royalties from Pfizer rose to $6.4 million from $4.5 million. The piece that still is not working is self-funding. Cash used in operations was still negative at $19.3 million, cash, equivalents, and restricted cash declined to $355.6 million, and the company kept buying back stock for $4.8 million while the business model still does not generate net cash.

A quick read could treat this quarter as a simple stabilization phase after the Labcorp divestiture. That would be too easy. Diagnostics did become leaner, but revenue from the continuing operations also fell because of lower testing volumes and reimbursement rates. Pharmaceuticals did grow, but part of that growth came from currency and partner-driven streams that the company does not fully control. The pipeline is progressing, but BARDA revenue declined, collaboration offsets to R&D were thin, and earlier-stage programs consumed more money.

In the prior annual analysis, the test for OPKO was clear: a leaner company had to prove it could fund itself. The first quarter closes a small part of that gap, mostly through cost cuts and smaller losses, but it does not change the test. 2026 remains a proof year. Over the next few reports, the market will look for three things: diagnostics moving closer to breakeven without disposal gains, royalties and partnerships covering a larger share of R&D, and capital management that does not require new dilution or additional monetization of high-quality assets.

The first-quarter economic map looks like this:

Events And Triggers

The first clean quarter after the oncology sale

The first trigger: the Labcorp oncology divestiture makes the year-over-year comparison less comfortable, but more useful. Service revenue fell by $30.7 million. Of that decline, $25.9 million came from the removal of the divested operations, and another $4.8 million came from lower clinical testing volumes and reimbursement rates in the continuing operations.

That means the revenue decline is not just a technical effect from a sold asset. The remaining business still has to show it can stabilize. On the positive side, diagnostics cost of revenue fell faster than revenue, 34% versus 30%, and SG&A fell 31%. That is why the segment’s operating loss narrowed to $13.0 million. On the weaker side, gross profit dollars still fell to $16.0 million from $18.3 million. The gross margin rate improved, but the absolute gross-profit base remains too narrow.

Pharmaceuticals look better, but not enough to carry the whole company

The second trigger: the pharmaceutical segment showed real improvement. Revenue rose to $52.0 million, gross profit rose to $29.7 million, and the operating loss narrowed to $29.7 million. The drivers were clear: a $2.4 million positive currency impact and stronger Spanish operations in products, NGENLA royalties rising to $6.4 million, $1.4 million from Eli Lilly, and $0.9 million from Regeneron.

The limitation is just as clear. Rayaldee was flat at $6.3 million of net revenue, and its sales deductions and allowance provision equaled 51% of gross Rayaldee sales. BARDA contributed $4.1 million compared with $7.0 million in the prior-year quarter. The segment is growing, but not from one broad, dominant engine. It is growing from a mix of currency, base products, royalties, and partner payments.

The buyback continues while cash is still being used

The third trigger: during the first quarter, the company repurchased 3.95 million shares at an average price of $1.21 per share, for a total cost of $4.8 million. Since the program began, total repurchases reached about $92.0 million, leaving about $108.0 million of remaining authorization.

The buyback signals confidence in the share price, but it cannot replace cash generation. In a quarter with negative operating cash flow and a $27.2 million all-in decline in cash, every dollar spent on buybacks is also a dollar not kept for pipeline funding, debt, or flexibility against legal risk. The move works only if the company can keep reducing operating burn.

A veteran director adds financial memory, not operating proof

The fourth trigger: on March 18, 2026, Subbarao V. Uppaluri was appointed to the board. He previously served as the company’s CFO from 2007 to 2012 and as a consultant until February 2014. He is expected to join the compensation committee, and the board determined that he is independent. This governance event can add financial memory and capital-allocation oversight, but it has no current operating or cash-flow effect. It helps frame the background, not the quarter’s results.

Efficiency, Profitability, And Competition

Diagnostics cut costs, but gross profit dollars did not grow

BioReference enters 2026 as a different segment than it was before the Labcorp sales. Less activity, fewer costs, less complexity. That shows clearly in the quarter: cost of revenue fell to $56.1 million, SG&A fell to $26.2 million, and diagnostics R&D is now nearly immaterial. On efficiency, this is progress.

The problem is that diagnostics gross profit fell to $16.0 million. Gross margin improved from about 17.8% to about 22.2%, but the dollar amount declined. That distinction matters. The company has learned to operate a smaller segment more efficiently, but it has not yet shown that the smaller segment produces enough gross profit to cover all remaining expenses.

Competition here is not only against other laboratories. It is also against a complicated reimbursement system. In the first quarter, the company recorded a $1.0 million positive revenue adjustment tied to prior-period implicit price concessions because of a favorable client-mix shift, compared with a $1.5 million negative adjustment in the prior-year quarter. That is a helpful swing, but it is also a reminder: the quality of diagnostics revenue depends on payer mix, reimbursement rules, test demand, and collection, not only on test volume.

Pharmaceutical gross profit improved, but expenses absorbed it

The pharmaceutical improvement is higher quality. Revenue rose 10%, cost of revenue declined slightly, and gross profit rose by $5.4 million. On the surface, this looks like a quarter in which the segment begins to show operating leverage.

The expense structure softens that read. Pharmaceutical R&D was $28.8 million, SG&A was $14.2 million, and amortization of intangible assets was $16.4 million. Together, those three layers are far above gross profit. The segment is still operating at a loss, even though revenue and gross profit improved.

R&D fell in the headline, but the mix became less comfortable

Pharmaceutical R&D fell to $28.8 million from $30.2 million. That looks like improvement. The internal breakdown makes it less clean. Biological product manufacturing expense fell to $4.9 million from $12.9 million, mainly because of the timing and reduction of discontinued BARDA COVID and BARDA FLU activity. At the same time, earlier-stage program spending rose to $9.5 million from $6.6 million, and Phase 3 spending rose to $1.8 million from a negligible amount.

External funding also weakened. Third-party grants and collaboration funding offset only $0.2 million of R&D, compared with $1.1 million in the prior-year quarter. So the decline in total R&D does not mean the pipeline became structurally cheaper. It means BARDA-related work fell while earlier-stage programs started taking up more room.

Cash Flow, Debt, And Capital Structure

The all-in cash picture is still negative

For OPKO, the relevant cash frame is all-in cash flexibility: how much cash remains after actual cash uses, including operating cash flow, reported capex, debt activity, lease cash, and buybacks. This is not a normalized cash-generation frame for a mature company before growth investment. The company is still at the stage where the question is how much time the cash balance buys, not just what the existing business earns in steady state.

In the first quarter, the company used $19.3 million in operating activities, $1.8 million in investing activities, and $5.2 million in financing activities. Within financing, $4.8 million went to share repurchases. Total lease-related cash outflow was $4.2 million, including $0.45 million of finance lease principal repayment. After a negative $0.9 million currency effect, cash, equivalents, and restricted cash fell from $382.7 million to $355.6 million.

The positive point is that operating cash burn improved meaningfully from $34.6 million in the prior-year quarter. The less comfortable point is that part of the improvement came from working capital: a $9.5 million accounts receivable inflow, a $7.0 million inflow from other current assets, and a $3.5 million increase in payables. That is real cash, but not necessarily a recurring quarterly bridge.

Debt looks better in the income statement, but it has not gone away

Interest expense fell to $10.9 million from $15.5 million, mainly because of lower interest on the 2029 notes after the exchange transaction. That is a clear positive. The $4.0 million decline in interest on the 2029 notes is one reason the net loss narrowed.

The debt stack still requires caution. The 2044 Royalty Financing Notes stood at $246.6 million and are secured by Pfizer profit-share payments. Their interest is three-month SOFR plus 7.5%, with a 4.0% floor. The 2029 convertible notes are carried at $87.3 million, but their principal amount is $121.4 million, and their fair value was estimated at $182.0 million. That gap matters because book value is not the full economic burden.

Known contractual obligations total $448.0 million. That includes $60.3 million for the remaining nine months of 2026, $94.6 million in 2029, and $257.6 million after 2030. These numbers do not point to an immediate twelve-month wall, but they keep the company dependent on cash access, partner revenue, and avoiding a sharp acceleration in spending.

The balance sheet still leans on non-liquid assets

Shareholders’ equity was $1.205 billion at quarter-end, but the equity line is not enough on its own. Goodwill of $482.3 million, intangible assets of $496.4 million, and IPR&D of $195.0 million add up to $1.174 billion, about 63% of total assets. This is a balance sheet with substantial accounting value, but less liquid flexibility.

That point is especially important in life sciences. Intangibles can become very valuable if a product succeeds, a partner advances, or royalties scale. But they do not fund quarterly losses by themselves. For that value to become accessible to shareholders, the assets need to move into commercialization, partnerships that cover expenses, or recurring cash flow.

Outlook

Four findings should lead the 2026 read:

• Diagnostics has moved from a size question to a quality question. After the oncology sale, lower revenue is acceptable if gross profit and operating loss improve. In the first quarter, the gross margin rate improved, but gross profit dollars declined.
• Pharmaceuticals is stronger, but still does not carry the company. NGENLA, Eli Lilly, Regeneron, and Spain helped growth, but the segment still lost almost $30 million from operations.
• BARDA is becoming a pace test. Revenue fell to $4.1 million, and $45.7 million remains to be recognized through February 2028, subject to performance and obligations.
• The company is buying time with existing cash, not positive cash flow. Burn improved, but the cash balance still fell and the buyback still uses cash.

2026 is a proof year, not a breakout year

Management believes existing cash, equivalents, and restricted cash are sufficient for operating needs and debt service beyond the next twelve months. That gives the company time. It does not solve the test. If the company accelerates development, starts additional trials, or acquires assets, it may need funding sooner than the static cash balance suggests.

That is why 2026 reads as a proof year. In diagnostics, the test is whether BioReference can narrow its loss for another quarter or two without relying only on costs that have already been removed. In pharmaceuticals, the test is whether NGENLA, Mazdutide, Regeneron, and BARDA generate enough recurring revenue or R&D offset so that development spending does not outrun external sources. In capital structure, the test is whether the buyback stays measured or becomes a burden while cash is still declining.

What has to happen over the next two to four quarters

The first requirement is stabilization in the continuing diagnostics business. The $4.8 million revenue decline beyond the removal of oncology has to stop. If it continues, cost savings will have a hard time carrying the segment.

The second requirement is better conversion of pharmaceutical revenue into profitability. In this quarter, pharmaceutical gross profit improved 22%, but the segment’s operating loss was still close to $30 million. For the market to treat the improvement as deeper, it has to flow through after R&D, SG&A, and amortization.

The third requirement is partnership execution. Regeneron contributed $0.9 million of revenue in the quarter, but the real value of that agreement arrives only if it selects and funds molecules in practice. BARDA remains an important funding framework, but revenue declined and the contract includes termination rights and performance assessments. Entera adds an LA-PTH track with 50/50 cost sharing, but it also adds another development program that needs budget.

The fourth requirement is continued reduction in operating cash burn. If operating cash flow approaches breakeven, the buyback looks like a reasonable capital-allocation tool. If burn returns to 2025 levels, the same buyback will look early.

What the market may miss

The market may focus on the sharp revenue decline and miss that the company did reduce losses after shrinking the business. That would miss the positive side. It may also focus on the narrower loss and miss that profitability is still far away, because diagnostics is losing money, pharmaceuticals is losing money, and corporate overhead remains fixed enough to matter.

The next report should be read less through consolidated revenue headlines and more through four lines: diagnostics gross profit, NGENLA and other royalties, BARDA revenue and R&D offsets, and operating cash flow. Those lines will decide whether the first quarter was a real improvement or mostly the base effect after asset sales.

Risks

The first risk is that diagnostics remains too small. The segment became leaner, but if testing volumes and reimbursement rates keep falling, the gross-profit base will not be enough. 4Kscore matters, but this quarter does not disclose enough product-level data to show that it is already large enough to change the segment’s economics by itself.

The second risk is that the pipeline consumes more cash than partnerships cover. In the ModeX analysis, this was the key question, and the first quarter did not close it. BARDA revenue fell, R&D offsets from partners were thin, and earlier-stage program spending rose. This does not mean the pipeline weakened scientifically. It means the economic coverage is still partial.

The third risk is capital structure. The 2044 notes are long-dated, but expensive and secured by Pfizer cash flows. The 2029 notes were not convertible at quarter-end, but their principal amount still exceeds the carrying value. If the company needs additional funding before operations approach breakeven, shareholders may again face dilution or early monetization of future value.

The fourth risk is legal and regulatory exposure. The Israeli tax assessment against OPKO Biologics is approximately $246 million including interest, and the matter is still awaiting judgment after trial and additional procedural steps. BioReference also operates under a five-year corporate integrity agreement signed in 2022 and continues to respond to document requests, audits, and investigations related to laboratory operations. This is not a prediction that the risk will crystallize, but it is large enough to remain part of the thesis.

The fifth risk is currency and tariffs. In the quarter, 32.7% of revenue was denominated in currencies other than the dollar, mainly the Chilean peso and the euro, and the company held $25.4 million of open forward contracts related to inventory purchases. The new U.S. tariff environment also includes a 15% tariff rate on qualifying patented pharmaceutical imports from the European Union, where the company’s principal international pharmaceutical manufacturing platforms are located. The first quarter was not materially affected, but it is a point to monitor.

The local short position does not indicate extreme pressure. Short interest was 0.50% of float on April 24, 2026, similar to the sector average, and SIR was 5.3. This is not a heavy short thesis. It is more a screen of caution and liquidity. If the company delivers another quarter of lower burn, there is no large local short position driving the story. If cash flow weakens, low short interest will not protect the fundamental read.

Conclusions

OPKO’s first quarter is better on the loss line, but still not good enough on self-funding. The company is smaller, the pharmaceutical business is stronger, and operating cash burn is lower. The main bottleneck remains unchanged: there is still no proof that the new core can fund R&D, debt, and buybacks without help from disposals, milestones, or additional capital.

Current conclusion: the first quarter improves the quality of the transition, but does not prove that the transition is complete.

What changed versus prior coverage is that the question is no longer theoretical. This is the first quarter in which oncology is out of the picture, so BioReference’s new shape can start to be tested. The early answer is mixed: the loss is smaller, but the business is still not profitable. ModeX and the partnership stack show the same pattern: there is progress, but economic coverage is not yet complete.

The strongest counter-thesis is that the market may be too harsh just as the company is getting closer to a better setup. If NGENLA keeps growing, if Mazdutide and Eli Lilly add royalties, if Regeneron and Merck advance programs, and if BioReference keeps narrowing losses, the first quarter could prove to be the start of convergence rather than another loss-making period. That is a real possibility, but it needs more operating evidence.

What could change the market’s interpretation over the near term is a run of two quarters in which operating cash flow approaches breakeven, NGENLA and partner revenue keep rising, and diagnostics narrows losses without another decline in continuing revenue. What would weaken the thesis is a return to high cash burn, another decline in testing volumes, or evidence that the pipeline needs more funding before partners carry more of the burden.

Why this matters: at OPKO, value does not sit only in products and partnerships. It sits in how much of that value remains for shareholders after debt, cash burn, dilution, and development spending.